These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8587854)

  • 1. Pharmacoeconomic issues in the treatment of depression.
    Saklad SR
    Pharmacotherapy; 1995; 15(6 Pt 2):76S-83S. PubMed ID: 8587854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using pharmacoeconomic data to compare antidepressant therapies.
    Manag Care; 2001 Aug; 10(8 Suppl):14-5; discussion 18-22. PubMed ID: 11729433
    [No Abstract]   [Full Text] [Related]  

  • 4. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does treatment of depression actually cost?
    Capitation Rates Data; 1999 Mar; 4(3):30-3. PubMed ID: 10724602
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder.
    Burke MJ; Silkey B; Preskorn SH
    J Clin Psychiatry; 1994 Sep; 55 Suppl A():42-52; discussion 53-4, 98-100. PubMed ID: 7961542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human cost of not achieving full remission in depression.
    McIntyre RS; O'Donovan C
    Can J Psychiatry; 2004 Mar; 49(3 Suppl 1):10S-16S. PubMed ID: 15147032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.
    Smith W; Sherrill A
    Med Interface; 1996 Jul; 9(7):88-92. PubMed ID: 10159282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of depression: direct and indirect; treatment versus nontreatment.
    Panzarino PJ
    J Clin Psychiatry; 1998; 59 Suppl 20():11-4. PubMed ID: 9881536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness measures of major depressive disorder in pharmacoeconomic evaluations.
    Casciano R
    Manag Care Interface; 2003; Suppl B():14-5. PubMed ID: 12647608
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct costs associated with depressive symptoms in late life: a 4.5-year prospective study.
    Luppa M; König HH; Heider D; Leicht H; Motzek T; Schomerus G; Riedel-Heller SG
    Int Psychogeriatr; 2013 Feb; 25(2):292-302. PubMed ID: 23083505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major depression: assessing the role of new antidepressants.
    Vanderhoff BT; Miller KE
    Am Fam Physician; 1997 Jan; 55(1):249-54, 259-60. PubMed ID: 9012282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could health care costs for depression be decreased if the disorder were correctly diagnosed and treated?
    Carta MG; Hardoy MC; Kovess V; Dell'Osso L; Carpiniello B
    Soc Psychiatry Psychiatr Epidemiol; 2003 Sep; 38(9):490-2. PubMed ID: 14504731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of depression--newer pharmacotherapies.
    Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
    Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.
    Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J
    J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
    McCombs JS; Ahn J; Tencer T; Shi L
    J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic and health outcome comparison of lithium and divalproex in a VA geriatric nursing home population: influence of drug-related morbidity on total cost of treatment.
    Conney J; Kaston B
    Am J Manag Care; 1999 Feb; 5(2):197-204. PubMed ID: 10346515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of antidepressant medications in the general practice setting. A critical review.
    Hegarty K; Ames D; Anderson J; Johnson C; McKinnon R; Moulds R
    Aust Fam Physician; 2003 Apr; 32(4):229-34, 236-7, 239 passim. PubMed ID: 12735262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.